Hormone therapy

• Health & Medicine

Apalutamide delays spread of certain prostate cancers in trial

An experimental hormone therapy delays the spread of prostate cancer that has stopped responding to standard treatment, according to new clinical trial results. An experimental hormone therapy delays the spread of prostate cancer that has stopped responding to standard treatment, according to new clinical trial results.

9 February 2018

• Health & Medicine

Adding abiraterone to standard treatment improves prostate cancer survival by 40 per cent

Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent. Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent.

3 June 2017

• Health & Medicine

Giving prostate cancer drug earlier extends lives of men whose disease has spread

Offering abiraterone (Zytiga) up-front with standard hormone treatment extends survival in men whose prostate cancer has spread. Offering abiraterone (Zytiga) up-front with standard hormone treatment extends survival in men whose prostate cancer has spread.

3 June 2017

• Health & Medicine

Hormone drug and radiotherapy ‘could extend lives’ of prostate cancer patients after surgery

Men with a high risk of prostate cancer recurrence could live longer if hormone treatment is given alongside radiotherapy after surgery. Men with a high risk of prostate cancer recurrence could live longer if hormone treatment is given alongside radiotherapy after surgery.

3 February 2017

• Health & Medicine

Naturally occurring symptoms may be mistaken for tamoxifen side-effects

Women taking tamoxifen to prevent breast cancer were less likely to continue taking the drug if they suffered nausea and vomiting, according to new data. Women taking tamoxifen to prevent breast cancer were less likely to continue taking the drug if they suffered nausea and vomiting, according to new data.

9 December 2016

• Health & Medicine

Staying on oestrogen-blocking drugs for five extra years 'prevents more breast cancers returning'

Women with the most common type of breast cancer could benefit from staying on key drugs for a decade, research suggests. Women with the most common type of breast cancer could benefit from staying on key drugs for a decade, research suggests.

6 June 2016

• Health & Medicine

Prostate cancer drug approved for routine use before chemotherapy

The National Institute for Health and Care Excellence (NICE) has approved the drug abiraterone for use before chemotherapy for prostate cancer The National Institute for Health and Care Excellence (NICE) has approved the drug abiraterone for use before chemotherapy for prostate cancer

21 March 2016

• Science & Technology
• Health & Medicine

NICE publishes new guidance for women at high risk of breast cancer

Almost half a million healthy women at high risk of breast cancer can now be offered drugs that can cut their chances of developing the disease. Almost half a million healthy women at high risk of breast cancer can now be offered drugs that can cut their chances of developing the disease.

25 June 2013

• Health & Medicine

Study confirms long term benefits of tamoxifen

Taking tamoxifen for 10 rather than five years halves the risk of women dying from the most common kind of breast cancer. Taking tamoxifen for 10 rather than five years halves the risk of women dying from the most common kind of breast cancer.

2 June 2013

• Health & Medicine

Oestrogen patches could offer a new treatment option for prostate cancer patients

Patches giving oestrogen through the skin could be an easy and safe alternative to the hormone therapies used to treat prostate cancer. Patches giving oestrogen through the skin could be an easy and safe alternative to the hormone therapies used to treat prostate cancer.

4 March 2013

• Health & Medicine

Trial reveals 10 years of tamoxifen halves later deaths from commonest kind of cancer

Ten years of tamoxifen treatment can approximately halve the number of deaths from the most common form of breast cancer during the second decade after diagnosis, according to the results of the Cancer Research UK- funded ATLAS trial published in the Lancet today. Ten years of tamoxifen treatment can approximately halve the number of deaths from the most common form of breast cancer during the second decade after diagnosis, according to the results of the Cancer Research UK- funded ATLAS trial published in the Lancet today.

5 December 2012

• Health & Medicine

Trial launched into testosterone replacement for male cancer survivors

Cancer Research UK is today launching a trial to see if male cancer survivors could benefit from hormone replacement therapy (HRT) with testosterone. Cancer Research UK is today launching a trial to see if male cancer survivors could benefit from hormone replacement therapy (HRT) with testosterone.

28 June 2012